Vericel Corp
VCELHealthcare·Biotechnology·USA·Mid·NASD·Nov 13 • 7:20 AM ET
57.40-0.02 (-0.03%)
2026-11-13 13:22 CET
Market cap
$2.93B
Revenue, TTM
324.17 USD m
Net income, TTM
33.31 USD m
Free cash flow, TTM
57.89 USD m
EPS diluted, TTM
0.63
90.85
Price
VCEL against its 20, 50 and 200-day averagesPatternshover a marker to name it
3.9% under the 52-week high of 59.75 on 11 Nov 2026. 52-week low 28.95 on 27 Mar 2026. Last 15 sessions, 51.5% high to low
Volume 0.00× normal · the line is the 50-bar volume average
Setup. RS line 30
CANSLIM 5 of 6 — fails: Performance: Year +50%
VCP 4 of 6 — fails: Average True Range: Under 2; RSI (14): Not Overbought (<60)
Minervini 3 of 4 — fails: Performance: Year +50%
Zanger 3 of 5 — fails: Performance: Week +10%; Relative Volume: Over 1.5
Leaders 4 of 5 — fails: Performance: Year +50%
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25
Value 0 of 4 — fails: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 1 of 4 — fails: Dividend Growth: Growing 2+ Years; P/E: Under 25 — not on the tape: Dividend Yield: Over 2%
Small Cap 3 of 4 — fails: Performance: Year +50%
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 2 of 3 — fails: Performance: Year +100%
Profile
VCEL52-week range, 92% of the way up
28.9559.75
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
| Index | RUT |
|---|---|
| Employees | 398 |
| IPO | Feb 04, 1997 |
| Beta | 1.03 |
| ATR, 14d | 2.40 |
| Rel volume | 0.00 |
| Short float | 10.64% |
| Insider own | 1.19% |
| Inst own | 107.75% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $2.93B |
| Enterprise Value | 2.85B |
| Income | 33.31M |
| Sales | 324.17M |
| Book / share | 7.53 |
| Cash / share | 3.34 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | 0.00% |
| Employees | 398 |
| IPO | Feb 04, 1997 |
Ratios
| Price / earnings | 90.85 |
|---|---|
| Forward price / earnings | 60.74 |
| Price / earnings / growth | 0.96 |
| Price / sales | 9.04 |
| Price / book | 7.63 |
| Price / cash | 17.20 |
| Price / free cash flow | 50.60 |
| Value / cash profit | 70.15 |
| Value / sales | 8.80 |
| Quick Ratio | 4.82 |
| Current Ratio | 5.13 |
| Debt / equity | 0.24 |
| Long-term debt / equity | 0.20 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | 0.63 |
|---|---|
| Earnings next year | 0.94 |
| Earnings next quarter | 0.57 |
| Earnings this year | 137.11% |
| Earnings next year | 24.55% |
| Earnings growth, 5 years | 63.33% |
| Past earnings growth | - 39.20% |
| Past sales growth | 18.90% 17.34% |
| Earnings vs last year | 147.62% |
| Sales vs last year | 25.30% |
| Earnings vs last quarter | 173.42% |
| Sales vs last quarter | 26.47% |
| Earnings | Nov 05 BMO |
| Surprise | 371.20% 9.47% |
Ownership
| Insiders own | 1.19% |
|---|---|
| Insider trades | -25.39% |
| Institutions own | 107.75% |
| Institution trades | -1.39% |
| Return on assets | 6.86% |
| Return on equity | 9.44% |
| Return on capital | 7.20% |
| Gross Margin | 74.47% |
| Operating margin | 8.32% |
| Profit Margin | 10.27% |
| 20-day average | 21.72% |
| 50-day average | 34.13% |
| 200-day average | 45.66% |
Technical
| Shares out | 51.04M |
|---|---|
| Shares floating | 50.42M |
| Short / float | 10.64% |
| Short ratio | 8.37 |
| Short interest | 5.36M |
| 52-week high | 59.75 -3.9% |
| 52-week low | 28.95 +98.3% |
| Volatility | 5.18% 5.04% |
| Average range | 2.40 |
| Strength index | 75.02 |
| Market sensitivity | 1.03 |
| Relative volume | 0.00 |
| Avg Volume | 640.78K |
| Volume | 50 |
Performance
| Perf Week | 5.09% |
|---|---|
| Perf Month | 39.93% |
| Perf Quarter | 31.68% |
| Perf Half Y | 73.78% |
| Perf YTD | 59.40% |
| Perf Year | 44.08% |
| Perf 3Y | 69.07% |
| Perf 5Y | 37.32% |
| Perf 10Y | 2451.11% |
| Recommendation | 1.25 |
| Target Price | 65.43 |
| Prev Close | 57.42 |
| Price | 57.40 |
| Change % | -0.03% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 17, 2025 | Downgrade | BTIG Research | Buy → Neutral | ||
| Aug 09, 2024 | Initiated | Canaccord Genuity | Buy | $57 | -0.7% |
| Jun 20, 2024 | Initiated | TD Cowen | Buy | $55 | -4.2% |
| Jan 25, 2024 | Upgrade | Truist | Hold → Buy | $39 → $51 | -11.1% |
| Aug 08, 2023 | Upgrade | BTIG Research | Neutral → Buy | $39 | -32.1% |
| Nov 10, 2022 | Downgrade | BTIG Research | Buy → Neutral | ||
| Nov 09, 2022 | Downgrade | Truist | Buy → Hold | ||
| Oct 14, 2022 | Resumed | Stephens | Overweight | $40 | -30.3% |
| Jan 11, 2021 | Downgrade | Oppenheimer | Outperform → Perform | ||
| Dec 18, 2020 | Initiated | Stephens | Overweight | $31 | -46.0% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| MDXG | Mimedx Group Inc | 472.80M |
| RCEL | AVITA Medical Inc | 397.44M |
| ANIK | Anika Therapeutics Inc | 184.99M |
| IART | Integra Lifesciences Holdings Corp | 1.16B |
| MESO | Mesoblast Ltd ADR | 1.70B |
| SNN | Smith & Nephew plc ADR | 13.02B |
| CNMD | Conmed Corp | 1.50B |
| BVS | Bioventus Inc | 894.00M |
| ORGO | Organogenesis Holdings Inc | 127.21M |
| SYK | Stryker Corp | 119.92B |
Insider trading
latest 14 of 100| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 09 '26 | Option Exercise | 43.63 | 25,000 | 1,090,750 | 41,186 | Nov 12 08:04 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 11 '26 | Option Exercise | 43.63 | 8 | 349 | 16,194 | Nov 12 08:04 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 09 '26 | Sale | 58.26 | 25,000 | 1,456,500 | 16,186 | Nov 12 08:04 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 11 '26 | Sale | 59.75 | 8 | 478 | 16,186 | Nov 12 08:04 PM |
| MCLAUGHLIN KEVIN F | Director | Nov 10 '26 | Option Exercise | 13.05 | 7,000 | 91,350 | 25,300 | Nov 12 07:48 PM |
| MCLAUGHLIN KEVIN F | Director | Nov 10 '26 | Sale | 58.96 | 7,000 | 412,720 | 18,300 | Nov 12 07:48 PM |
| ZERBE ROBERT L MD | Director | Nov 09 '26 | Option Exercise | 13.05 | 2,000 | 26,100 | 34,995 | Nov 12 07:43 PM |
| ZERBE ROBERT L MD | Director | Nov 09 '26 | Sale | 57.88 | 2,000 | 115,760 | 32,995 | Nov 12 07:43 PM |
| Mara Joseph Anthony Jr | Officer | Nov 11 '26 | Proposed Sale | 59.75 | 8 | 478 | Nov 12 07:23 AM | |
| MCLAUGHLIN KEVIN F | Director | Nov 10 '26 | Proposed Sale | 58.39 | 7,000 | 408,730 | Nov 10 03:44 PM | |
| ZERBE ROBERT L MD | Director | Nov 09 '26 | Proposed Sale | 57.88 | 2,000 | 115,753 | Nov 09 04:29 PM | |
| Mara Joseph Anthony Jr | Officer | Nov 09 '26 | Proposed Sale | 58.26 | 25,000 | 1,456,544 | Nov 09 04:16 PM | |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 06 '26 | Option Exercise | 32.32 | 28,641 | 925,540 | 30,759 | Nov 09 04:05 PM |
| Mara Joseph Anthony Jr | Chief Financial Officer | Nov 05 '26 | Option Exercise | 32.42 | 21,359 | 692,460 | 27,118 | Nov 09 04:05 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| IJR | iShares Core S&P Small-Cap ETF | AUM: 107.13B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| SPSM | State Street SPDR Portfolio S&P 600TM Small Cap ETF | AUM: 16.19B |
| IJT | iShares S&P Small-Cap 600 Growth ETF | AUM: 7.52B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
News
latest 14 of 200- MediWound's Burn Drug Is Gaining Speed. Its Next Target Could Be Much Bigger (NASDAQ: MDWD) (FinanceWire)
- Vericel Delivers Its Strongest Beat-And-Raise Of 2026, But Burn Care Spike And A Cautious 2027 Signal Temper The Story (Earnings Whispers) +13.85%
- Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance (GlobeNewswire)
- Vericel Must Prove Its Second-Half Macy Slowdown Is Caution, Not Reality (Earnings Whispers) -5.04%
- Vericel to Report Third Quarter 2026 Financial Results on November 5, 2026 (GlobeNewswire)
- Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD) (FinanceWire)
- Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 (GlobeNewswire)
- Next GLP-1 Billion-Dollar Market: Fireside Chat with Conexeu Sciences CEO Miles Harrison (IPO-Edge.com)
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program (GlobeNewswire)
- Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire)
- Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026 (GlobeNewswire)
- Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD) (FinanceWire)
- Vericel to Present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026 (GlobeNewswire)
- Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance (GlobeNewswire)
Quarterly earnings
2026Q3 EPS 0.270 beat 0.057, from 0.100 a year earlier. Sales 85.37 beat 77.99, from 67.50 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-05 08:30 | 0.270 | 0.057 | 0.270 | 85.37 | 77.99 | EPS +371.2% · sales +9.5% | vs 2025Q3, year-ago quarter · EPS +170.0% · sales +26.5% | 8 | Open +11.13% vs SPY -0.17%. Close +13.85% vs SPY -4.41% |
| 2026Q2ended 2026-06-30 | 2026-07-30 08:30 | 0.040 | -0.029 | 0.042 | 77.46 | 72.70 | EPS -238.4% · sales +6.5% | vs 2025Q2, year-ago quarter · EPS -500.0% · sales +22.5% | 8 | Open +4.89% vs SPY +0.90%. Close +2.12% vs SPY +1.68% |
| 2026Q1ended 2026-03-31 | 2026-05-07 08:30 | -0.120 | -0.153 | -0.124 | 68.43 | 63.68 | EPS -21.5% · sales +7.5% | vs 2025Q1, year-ago quarter · EPS -47.8% · sales +30.1% | 8 | Open +10.11% vs SPY +0.17%. Close -4.49% vs SPY -0.31% |
| 2025Q4ended 2025-12-31 | 2026-02-26 08:30 | 0.450 | 0.391 | 0.446 | 92.92 | 90.97 | EPS +15.1% · sales +2.1% | vs 2024Q4, year-ago quarter · EPS +18.4% · sales +23.3% | 8 | Open +0.59% vs SPY +0.02%. Close +1.59% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-06 08:30 | 0.100 | -0.006 | 0.098 | 67.50 | 64.56 | EPS -1687.3% · sales +4.6% | vs 2024Q3, year-ago quarter · EPS -600.0% · sales +16.6% | 8 | Open +11.88% vs SPY -0.16%. Close +4.17% vs SPY -1.07% |
| 2025Q2ended 2025-06-30 | 2025-07-31 08:30 | -0.010 | -0.032 | -0.011 | 63.24 | 64.48 | EPS -68.5% · sales -1.9% | vs 2024Q2, year-ago quarter · EPS -90.0% · sales +20.1% | 8 | Open -9.05% vs SPY +0.79%. Close -14.07% vs SPY -0.38% |
| 2025Q1ended 2025-03-31 | 2025-05-08 08:30 | -0.230 | -0.124 | -0.225 | 52.60 | 53.80 | EPS +86.1% · sales -2.2% | vs 2024Q1, year-ago quarter · EPS +187.5% · sales +2.6% | 8 | Open -0.54% vs SPY +0.73%. Close +3.46% vs SPY +0.70% |
| 2024Q4ended 2024-12-31 | 2025-02-27 08:30 | 0.380 | 0.320 | 0.379 | 75.38 | 76.51 | EPS +18.9% · sales -1.5% | vs 2023Q4, year-ago quarter · EPS +46.2% · sales +16.0% | 8 | Open +3.75% vs SPY +0.39%. Close -6.11% vs SPY -1.60% |
| 2024Q3ended 2024-09-30 | 2024-11-07 08:30 | -0.020 | -0.048 | -0.018 | 57.91 | 55.21 | EPS -58.5% · sales +4.9% | vs 2023Q3, year-ago quarter · EPS -75.0% · sales +27.0% | 7 | Open +2.48% vs SPY +0.35%. Close +4.14% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-01 08:30 | -0.100 | -0.093 | -0.096 | 52.66 | 52.59 | EPS +7.6% · sales +0.1% | vs 2023Q2, year-ago quarter · EPS -9.1% · sales +14.7% | 7 | Open -3.94% vs SPY +0.32%. Close -5.94% vs SPY -1.42% |
| 2024Q1ended 2024-03-31 | 2024-05-08 08:30 | -0.080 | -0.110 | -0.080 | 51.28 | 49.07 | EPS -27.4% · sales +4.5% | vs 2023Q1, year-ago quarter · EPS -50.0% · sales +25.0% | 6 | Open -7.11% vs SPY -0.36%. Close -3.70% vs SPY +0.01% |
| 2023Q4ended 2023-12-31 | 2024-02-29 08:30 | 0.260 | 0.174 | 0.257 | 65.00 | 63.95 | EPS +49.7% · sales +1.6% | vs 2022Q4, year-ago quarter · EPS +116.7% · sales +23.3% | 5 EPS · 6 sales | Open +2.99% vs SPY +0.36%. Close -4.44% vs SPY +0.36% |
| 2023Q3ended 2023-09-30 | 2023-11-08 08:30 | -0.080 | -0.121 | -0.077 | 45.58 | 45.14 | EPS -34.0% · sales +1.0% | vs 2022Q3, year-ago quarter · EPS -42.9% · sales +18.2% | 6 | - |
| 2023Q2ended 2023-06-30 | 2023-08-02 08:30 | -0.110 | -0.152 | -0.106 | 45.92 | 42.14 | EPS -27.5% · sales +9.0% | vs 2022Q2, year-ago quarter · EPS -42.1% · sales +24.0% | 5 | - |
| 2023Q1ended 2023-03-31 | 2023-05-10 08:30 | -0.160 | -0.153 | -0.158 | 41.02 | 37.88 | EPS +4.4% · sales +8.3% | vs 2022Q1, year-ago quarter · EPS +6.7% · sales +13.7% | 5 | - |
| 2022Q4ended 2022-12-31 | 2023-02-23 08:30 | 0.120 | 0.036 | 0.120 | 52.69 | 52.88 | EPS +233.3% · sales -0.4% | vs 2021Q4, year-ago quarter · EPS +33.3% · sales +10.7% | 5 | - |
Annual earnings
2025FY EPS 0.320 beat 0.266, from 0.200 a year earlier. Sales 276.26 beat 274.37, from 237.22 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 2.800 | - | - | 666.11 | 20.50 |
| 2029FYestimate | - | 1.870 | - | - | 536.31 | 30.70 |
| 2028FYestimate | - | 1.394 | - | - | 459.67 | 41.17 |
| 2027FYestimate | - | 0.945 | - | - | 398.34 | 60.74 |
| 2026FYestimate | - | 0.759 | - | - | 345.27 | 75.65 |
| 2025FY | 0.320 | 0.266 | 0.320 | 276.26 | 274.37 | 112.53 |
| 2024FY | 0.200 | 0.136 | 0.201 | 237.22 | 238.38 | 274.55 |
| 2023FY | -0.070 | -0.160 | -0.067 | 197.52 | 196.46 | - |
| 2022FY | -0.350 | -0.444 | -0.355 | 164.37 | 164.57 | - |
| 2021FY | -0.160 | -0.112 | -0.161 | 156.18 | 157.58 | - |
| 2020FY | 0.060 | 0.007 | 0.061 | 124.18 | 123.94 | 514.67 |
| 2019FY | -0.220 | -0.232 | -0.219 | 117.85 | 117.45 | - |
| 2018FY | -0.200 | -0.274 | -0.202 | 90.86 | 88.22 | - |
| 2017FY | -0.520 | -0.605 | -0.520 | 63.92 | 59.16 | - |
| 2016FY | -1.180 | -0.943 | -1.180 | 54.38 | 53.94 | - |
| 2015FY | -0.970 | -0.835 | -0.970 | 51.17 | 53.08 | - |
| 2014FY | -2.230 | -2.693 | -2.230 | 28.80 | 24.79 | - |
| 2013FY | -6.950 | - | -6.950 | 0.02 | - | - |
| 2012FY | -16.200 | -16.600 | -16.200 | 0.02 | 0.00 | - |
| 2011FY | -10.200 | -13.603 | -10.200 | 0.02 | 0.00 | - |
| 2010FY | -14.400 | -14.400 | -14.400 | 0.09 | 0.09 | - |
Quarterly results
2026Q3 revenue 85.37, from 67.50 a year earlier. Operating margin 14.3%, from 5.1% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E 0.76 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-09 | 0.76 | +2.5% |
| 2026Q4 | E | per share | 2026-11-09 | 0.57 | -1.3% |
| 2026FY | R | per share | 2026-11-09 | 0.76 | +2.5% |
| 2026Q4 | R | per share | 2026-11-09 | 0.57 | -1.3% |
| 2026FY | S | - | 2026-11-09 | 345.27 | +0.4% |
| 2026Q4 | S | - | 2026-11-09 | 114.02 | +0.2% |
| 2026Q3 | E | per share | 2026-11-03 | 0.06 | -0.3% |
| 2026Q3 | R | per share | 2026-11-03 | 0.06 | -0.3% |
| 2026Q3 | S | per share | 2026-11-03 | 77.95 | 0.0% |
| 2026Q2 | E | per share | 2026-07-21 | -0.03 | 0.0% |
| 2026Q2 | R | per share | 2026-07-21 | -0.03 | 0.0% |
| 2026Q2 | S | per share | 2026-07-21 | 72.69 | 0.0% |
| 2026Q1 | S | per share | 2026-04-23 | 63.68 | 0.0% |
| 2026Q1 | E | per share | 2026-04-10 | -0.15 | -0.6% |
| 2026Q1 | R | per share | 2026-04-10 | -0.15 | -0.6% |
| 2025FY | E | per share | 2026-02-26 | 0.28 | +4.4% |
| 2025Q4 | E | per share | 2026-02-26 | 0.41 | +4.7% |
| 2025FY | R | per share | 2026-02-26 | 0.28 | +4.4% |
| 2025Q4 | R | per share | 2026-02-26 | 0.41 | +4.7% |
| 2025Q4 | S | per share | 2026-02-26 | 90.95 | 0.0% |
| 2025FY | S | - | 2026-02-26 | 274.48 | +0.0% |
| 2025Q3 | E | per share | 2025-10-14 | -0.01 | 0.0% |
| 2025Q3 | R | per share | 2025-10-14 | -0.01 | 0.0% |
| 2025Q3 | S | per share | 2025-10-14 | 64.56 | 0.0% |
| 2025Q2 | E | per share | 2025-07-27 | -0.03 | 0.0% |
| 2025Q2 | R | per share | 2025-07-27 | -0.03 | 0.0% |
| 2025Q2 | S | per share | 2025-07-27 | 64.52 | 0.0% |
| 2025Q1 | E | per share | 2025-04-17 | -0.12 | -7.5% |
| 2025Q1 | R | per share | 2025-04-17 | -0.12 | -7.5% |
| 2025Q1 | S | per share | 2025-04-17 | 53.80 | -0.1% |
| 2024FY | E | per share | 2025-02-18 | 0.14 | 0.0% |
| 2024Q4 | E | per share | 2025-02-18 | 0.32 | 0.0% |
| 2024FY | R | per share | 2025-02-18 | 0.14 | 0.0% |
| 2024Q4 | R | per share | 2025-02-18 | 0.32 | 0.0% |
| 2024Q4 | S | per share | 2025-01-30 | 76.51 | -0.2% |
| 2024FY | S | - | 2025-01-30 | 238.38 | -0.1% |
| 2024Q3 | E | per share | 2024-11-06 | -0.05 | 0.0% |
| 2024Q3 | R | per share | 2024-11-06 | -0.05 | 0.0% |
| 2024Q3 | S | per share | 2024-10-15 | 55.21 | 0.0% |
| 2024Q2 | E | per share | 2024-07-22 | -0.09 | 0.0% |
| 2024Q2 | R | per share | 2024-07-22 | -0.09 | 0.0% |
| 2024Q2 | S | per share | 2024-07-22 | 52.59 | 0.0% |
| 2024Q1 | E | per share | 2024-04-12 | -0.11 | -0.3% |
| 2024Q1 | R | per share | 2024-04-12 | -0.11 | -0.3% |
| 2024Q1 | S | per share | 2024-04-12 | 49.07 | 0.0% |
| 2023FY | E | per share | 2024-01-26 | -0.16 | -0.9% |
| 2023FY | R | per share | 2024-01-26 | -0.16 | -0.9% |
| 2023FY | S | - | 2024-01-26 | 196.46 | +0.3% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.52 | -0.202 | -0.219 | 0.061 | -0.161 | -0.355 | -0.067 | 0.201 | 0.317 | 0.6318 | - |
| Sales USD millions | 64 | 91 | 118 | 124 | 156 | 164 | 198 | 237 | 276 | 324 | - |
| Shares million shares | 36 | 44 | 45 | 46 | 47 | 47 | 48 | 50 | 51 | - | 51 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.018 | 0.379 | -0.225 | -0.011 | 0.098 | 0.446 | -0.124 | 0.042 | 0.267 |
| Sales USD millions | 58 | 75 | 53 | 63 | 68 | 93 | 68 | 77 | 85 |
| Shares million shares | 49 | 50 | 50 | 50 | 51 | 51 | 51 | 51 | 51 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 324.17 | 276.26+16.5% | 237.22+20.1% | 197.52+20.2% | 164.37+5.2% | 156.18+25.8% | 124.18+5.4% | 117.85+29.7% | 90.86 |
| Cost of Goods Sold Incl. D&A | 82.77 | 70.66+8.5% | 65.12+5.1% | 61.94+13.5% | 54.58+8.8% | 50.16+25.6% | 39.95+6.3% | 37.57+16.8% | 32.16 |
| Gross Profit | 241.41 | 205.60+19.5% | 172.11+26.9% | 135.58+23.5% | 109.79+3.5% | 106.03+25.9% | 84.23+4.9% | 80.28+36.8% | 58.70 |
| Selling, General and Administrative Excl. Other | 214.44 | 194.56+16.1% | 167.59+18.0% | 142.04+12.0% | 126.85+11.4% | 113.88+39.1% | 81.86-10.6% | 91.53+46.2% | 62.61 |
| Research and Development | 29.73 | 27.56+11.1% | 24.80+17.9% | 21.04+5.5% | 19.94+22.4% | 16.29+25.1% | 13.02-57.2% | 30.39+123.5% | 13.60 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 26.97 | 11.04+144.2% | 4.52 | -6.46 | -17.06 | -7.85-431.2% | 2.37 | -11.25 | -3.91 |
| Interest Expense | 0.64 | 0.63+3.3% | 0.61+1.7% | 0.60+62.2% | 0.37 | 0.00-100.0% | 0.010.0% | 0.01-99.4% | 1.73 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 3.36 |
| Net Income Before Taxes | 34.17 | 17.38+65.4% | 10.51 | -2.37 | -15.99 | -7.58-349.3% | 3.04 | -9.66 | -8.14 |
| Income Taxes | 0.86 | 0.86+473.3% | 0.15-81.5% | 0.81+12.5% | 0.72 | -0.11-161.1% | 0.18 | 0.00 | 0.00 |
| Consolidated Net Income | 33.31 | 16.52+59.5% | 10.36 | -3.18 | -16.71 | -7.47-361.2% | 2.86 | -9.66 | -8.14 |
| Net Income From Continuing Operations | 33.31 | 16.52+59.5% | 10.36 | -3.18 | -16.71 | -7.47-361.2% | 2.86 | -9.66 | -8.14 |
| Net Income | 33.31 | 16.52+59.5% | 10.36 | -3.18 | -16.71 | -7.47-361.2% | 2.86 | -9.66 | -8.14 |
| EPS (Recurring) per share | 0.63 | 0.32+60.0% | 0.20 | -0.07 | -0.35 | -0.16-366.7% | 0.06 | -0.22 | -0.14 |
| EPS (Basic, Before Extraordinaries) per share | 0.66 | 0.33+57.1% | 0.21 | -0.07 | -0.35 | -0.16-366.7% | 0.06 | -0.22 | -0.20 |
| EPS (Diluted) per share | 0.63 | 0.32+60.0% | 0.20 | -0.07 | -0.35 | -0.16-366.7% | 0.06 | -0.22 | -0.20 |
| EBITDA | 40.65 | 22.59+125.4% | 10.02 | -1.83 | -8.86 | -0.47-105.1% | 9.20 | -6.72 | -2.48 |
| Non-Operating Income (Expense) | 7.84 | 6.96+5.3% | 6.61+40.6% | 4.70+226.4% | 1.44+414.3% | 0.28-58.8% | 0.68-57.2% | 1.59+82.8% | 0.87 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 34.85 | 30.63+6.2% | 28.83+12.9% | 25.54-13.0% | 29.37+17.2% | 25.06+147.9% | 10.11-23.3% | 13.18+82.5% | 7.22 |
| Price To Earnings Ratio ratio statement ratio, not the snapshot | 90.88 | 90.88 | 878.56 | - | - | - | 724.88 | - | - |
| Price To Sales Ratio ratio | 6.56 | 6.80 | 11.96 | 8.58 | 7.55 | 11.69 | 11.76 | 6.52 | 7.71 |
| Gross Margin % | 74.47 | 74.42 | 72.55 | 68.64 | 66.80 | 67.88 | 67.83 | 68.12 | 64.60 |
| Operating Margin % | 8.32 | 4.00 | 1.90 | -3.27 | -10.38 | -5.03 | 1.91 | -9.55 | -4.30 |
| Net Margin % | 10.27 | 5.98 | 4.37 | -1.61 | -10.17 | -4.78 | 2.31 | -8.20 | -8.96 |
| Shares Outstanding million shares | 51.04 | 50.62+2.0% | 49.63+3.8% | 47.83+1.2% | 47.25+0.8% | 46.88+2.4% | 45.80+2.1% | 44.86+2.9% | 43.58 |
| Market Capitalization | 2,930.13 | 2,930.13+8.1% | 2,710.27+59.5% | 1,699.47+36.6% | 1,243.85-32.4% | 1,839.84+31.2% | 1,402.84+80.4% | 777.69+3.1% | 754.24 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 85.37+26.5% | 77.46+22.5% | 68.42+30.1% | 92.92+23.3% | 67.50+16.6% | 63.24+20.1% | 52.60+2.6% | 75.38+16.0% |
| Cost of Goods Sold Incl. D&A | 22.76+27.0% | 21.05+26.6% | 19.16+17.4% | 19.79+17.2% | 17.92+10.3% | 16.63+3.5% | 16.32+2.4% | 16.88+2.4% |
| Gross Profit | 62.61+26.3% | 56.40+21.0% | 49.27+35.8% | 73.13+25.0% | 49.59+19.1% | 46.61+27.3% | 36.27+2.6% | 58.50+20.6% |
| Selling, General and Administrative Excl. Other | 50.42+9.3% | 55.97+15.1% | 57.33+16.9% | 50.71+26.7% | 46.13+4.6% | 48.64+14.1% | 49.06+20.2% | 40.02+11.9% |
| Research and Development | 6.88+8.9% | 7.49+11.3% | 8.10+11.6% | 7.25+47.4% | 6.32+3.8% | 6.73-8.6% | 7.26+13.1% | 4.92+0.4% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 12.19+253.3% | 0.43 | -8.06 | 22.41+21.3% | 3.45 | -2.03 | -12.79 | 18.48+45.2% |
| Interest Expense | 0.160.0% | 0.160.0% | 0.16+6.7% | 0.16+6.7% | 0.16+6.7% | 0.16+6.7% | 0.150.0% | 0.15-6.3% |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | 14.16+179.3% | 2.21 | -6.30 | 24.10+20.8% | 5.07 | -0.55 | -11.25 | 19.95+41.6% |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.86+473.3% | 0.00 | 0.00 | 0.00 | 0.15-86.4% |
| Consolidated Net Income | 14.16+179.3% | 2.21 | -6.30 | 23.24+17.3% | 5.07 | -0.55 | -11.25 | 19.81+52.5% |
| Net Income From Continuing Operations | 14.16+179.3% | 2.21 | -6.30 | 23.24+17.3% | 5.07 | -0.55 | -11.25 | 19.81+52.5% |
| Net Income | 14.16+179.3% | 2.21 | -6.30 | 23.24+17.3% | 5.07 | -0.55 | -11.25 | 19.81+52.5% |
| EPS (Recurring) per share | 0.27+170.0% | 0.04 | -0.12 | 0.45+18.4% | 0.10 | -0.01 | -0.23 | 0.38+46.2% |
| EPS (Basic, Before Extraordinaries) per share | 0.28+180.0% | 0.04 | -0.12 | 0.46+15.0% | 0.10 | -0.01 | -0.23 | 0.40+48.1% |
| EPS (Diluted) per share | 0.27+170.0% | 0.04 | -0.12 | 0.45+18.4% | 0.10 | -0.01 | -0.23 | 0.38+46.2% |
| EBITDA | 15.89+148.7% | 4.05+406.2% | -4.80 | 25.50+27.8% | 6.39 | 0.80 | -10.11 | 19.96+43.8% |
| Non-Operating Income (Expense) | 2.13+19.7% | 1.93+18.4% | 1.92+12.9% | 1.85+13.5% | 1.78+3.5% | 1.63+8.7% | 1.70-2.9% | 1.63+7.2% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 7.82-10.1% | 9.08-10.5% | 11.29-1.9% | 6.65+6.4% | 8.70-5.6% | 10.14+6.5% | 11.51+48.1% | 6.25+14.5% |
| Price To Earnings Ratio ratio statement ratio, not the snapshot | 90.88 | 108.78 | 104.52 | 149.54 | 252.37 | 1,077.22 | 241.71 | 878.56 |
| Price To Sales Ratio ratio | 6.56 | 7.60 | 5.59 | 6.79 | 6.31 | 8.60 | 9.33 | 12.08 |
| Gross Margin % | 73.34 | 72.82 | 72.00 | 78.70 | 73.46 | 73.71 | 68.96 | 77.61 |
| Operating Margin % | 14.27 | 0.56 | -11.79 | 24.12 | 5.11 | -3.21 | -24.32 | 24.52 |
| Net Margin % | 16.59 | 2.85 | -9.21 | 25.01 | 7.52 | -0.87 | -21.38 | 26.28 |
| Shares Outstanding million shares | 51.04+1.0% | 51.17+1.4% | 51.01+1.5% | 50.62+2.0% | 50.55+2.6% | 50.44+3.2% | 50.25+3.6% | 49.63+3.8% |
| Market Capitalization | 2,930.13+84.5% | 2,272.02+6.1% | 1,633.06-27.0% | 1,821.17-32.8% | 1,587.98-23.3% | 2,142.09-3.9% | 2,237.06-10.9% | 2,710.27+59.5% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 137.50+8.5% | 126.74-0.5% | 127.33+6.5% | 119.54+15.6% | 103.40+36.4% | 75.81+8.7% | 69.72-15.9% | 82.92+208.7% | 26.86 |
| Short Term Receivables | 84.63+37.9% | 61.38+5.2% | 58.36+25.4% | 46.54+24.3% | 37.44+8.5% | 34.50+7.2% | 32.17+37.2% | 23.45+28.4% | 18.27 |
| Inventories | 17.56+1.1% | 17.37+32.7% | 13.09-18.1% | 15.99+19.5% | 13.38+42.9% | 9.36+37.2% | 6.82+91.6% | 3.56-6.1% | 3.79 |
| Other Current Assets | 7.74+6.2% | 7.29+6.4% | 6.85+42.7% | 4.80+12.9% | 4.25+9.3% | 3.89+31.9% | 2.95+3.5% | 2.85+80.4% | 1.58 |
| Total Current Assets | 247.44+16.3% | 212.78+3.5% | 205.63+10.0% | 186.87+17.9% | 158.46+28.2% | 123.56+10.7% | 111.66-1.0% | 112.78+123.3% | 50.51 |
| Net Property, Plant & Equipment | 173.17-0.1% | 173.26+50.5% | 115.10+100.6% | 57.37-2.8% | 59.03+2.2% | 57.74+79.0% | 32.25+445.7% | 5.91+45.2% | 4.07 |
| Total Investments and Advances | 61.40+54.0% | 39.88+57.8% | 25.28+26.7% | 19.96-22.9% | 25.90+6.5% | 24.31+160.3% | 9.34 | 0.00 | 0.00 |
| Intangible Assets | 5.62-10.1% | 6.25-9.2% | 6.88-8.3% | 7.50 | - | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.34-39.3% | 0.56-27.3% | 0.77-40.8% | 1.30+306.3% | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 487.97+12.8% | 432.72+22.4% | 353.66+29.5% | 273.00+12.0% | 243.71+18.5% | 205.61+34.2% | 153.24+29.1% | 118.69+117.5% | 54.58 |
| Short Term Debt Incl. Current Port. of LT Debt | 14.09+50.4% | 9.37+51.4% | 6.19+42.6% | 4.34+45.2% | 2.99-32.5% | 4.43-19.5% | 5.50 | 0.00-100.0% | 0.35 |
| Accounts Payable | 15.83-33.6% | 23.85+6.7% | 22.35+32.0% | 16.93+87.7% | 9.02+33.6% | 6.75+6.5% | 6.34-10.8% | 7.11+28.1% | 5.55 |
| Other Current Liabilities | 19.24+12.7% | 17.07-0.8% | 17.21+6.3% | 16.19+15.3% | 14.04+24.4% | 11.29+42.0% | 7.95+3.5% | 7.68+6.8% | 7.19 |
| Total Current Liabilities | 49.15-2.3% | 50.29+9.9% | 45.75+22.1% | 37.46+43.8% | 26.05+15.9% | 22.48+13.5% | 19.80+33.9% | 14.79+13.0% | 13.09 |
| Long Term Debt | 84.18-7.0% | 90.47+10.4% | 81.96+89.4% | 43.27-8.3% | 47.19-3.4% | 48.87+118.7% | 22.35 | 0.00-100.0% | 16.89 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.67-18.9% | 2.06 |
| Total Liabilities | 133.33-5.3% | 140.75+10.2% | 127.70+58.2% | 80.73+10.2% | 73.24+2.6% | 71.35+69.3% | 42.15+156.1% | 16.46-48.6% | 32.04 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 354.64+21.5% | 291.97+29.2% | 225.95+17.5% | 192.27+12.8% | 170.46+27.0% | 134.26+20.9% | 111.09+8.7% | 102.23+353.5% | 22.54 |
| Total Shareholders Equity | 354.64+21.5% | 291.97+29.2% | 225.95+17.5% | 192.27+12.8% | 170.46+27.0% | 134.26+20.9% | 111.09+8.7% | 102.23+353.5% | 22.54 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 354.64+21.5% | 291.97+29.2% | 225.95+17.5% | 192.27+12.8% | 170.46+27.0% | 134.26+20.9% | 111.09+8.7% | 102.23+353.5% | 22.54 |
| Total Liabilities & Stockholders Equity | 487.97+12.8% | 432.72+22.4% | 353.66+29.5% | 273.00+12.0% | 243.71+18.5% | 205.61+34.2% | 153.24+29.1% | 118.69+117.5% | 54.58 |
| Book Value Per Share per share | 7.01+19.2% | 5.88+24.6% | 4.72+16.0% | 4.07+11.8% | 3.64+24.2% | 2.93+18.1% | 2.48+5.5% | 2.35+273.0% | 0.63 |
| Tangible Book Value Per Share per share | 6.89+19.6% | 5.76+25.8% | 4.58+17.1% | 3.91+7.4% | 3.64+24.2% | 2.93+18.1% | 2.48+5.5% | 2.35+273.0% | 0.63 |
| Full-Time Employees people | 398+11.5% | 357+13.7% | 314+3.0% | 305+8.5% | 281+2.9% | 273+13.3% | 241+11.6% | 216+5.4% | 205 |
| Price to Book Ratio ratio | 7.63 | 10.51 | 8.31 | 6.99 | 10.81 | 10.54 | 7.03 | 7.42 | 11.35 |
| Return on Assets % | 3.59 | 2.64 | -1.02 | -6.47 | -3.33 | 1.60 | -7.11 | -9.39 | -33.51 |
| Return on Equity % | 5.11 | 4.00 | -1.52 | -9.21 | -4.90 | 2.33 | -9.06 | -13.04 | -73.17 |
| Return on Invested Capital % | 3.76 | 2.71 | -1.03 | -7.09 | -3.43 | 1.56 | -7.24 | -7.96 | -43.84 |
| Quick Ratio ratio | 4.68 | 3.89 | 4.21 | 4.56 | 5.57 | 5.08 | 5.30 | 7.38 | 3.57 |
| Current Ratio ratio | 5.03 | 4.23 | 4.49 | 4.99 | 6.08 | 5.50 | 5.64 | 7.62 | 3.86 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | 33.31 | 16.52+59.5% | 10.36 | -3.18 | -16.71 | -7.47-361.2% | 2.86 | -9.66 | -8.14 |
| Depreciation | 13.60 | 11.54+109.8% | 5.50+18.8% | 4.63-43.5% | 8.20+11.0% | 7.39+8.2% | 6.83+50.8% | 4.53+216.8% | 1.43 |
| Other Funds (Non Cash) | 43.71 | 45.20+5.7% | 42.75+13.0% | 37.83+4.1% | 36.33+3.0% | 35.28+147.6% | 14.25+13.0% | 12.61+22.1% | 10.33 |
| Funds from Operations | 90.62 | 73.27+25.0% | 58.61+49.2% | 39.27+41.2% | 27.82-20.9% | 35.19+46.9% | 23.95+220.2% | 7.48+106.6% | 3.62 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -25.31 | -21.36 | -0.45 | -3.96 | -11.21 | -6.15 | -6.37 | -14.66 | -4.03 |
| Cash from Operating Activities | 65.31 | 51.91-10.7% | 58.16+64.7% | 35.31+112.6% | 16.61-42.8% | 29.04+65.3% | 17.57 | -7.18 | -0.41 |
| Capital Expenditures | -7.42 | -27.16 | -63.97 | -27.51 | -7.60 | -7.92 | -2.63 | -2.62 | -2.68 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Purchase or Sale of Investments | -18.70 | -16.77 | -15.06-161.8% | 24.38 | -28.61-748.8% | 4.41 | -14.53-209.8% | 13.23 | -64.35 |
| Purchase of Investments | -68.51 | -72.37 | -68.21 | -55.23 | -69.55 | -60.02 | -63.06 | -72.35 | -66.55 |
| Sale Or Maturity of Investments | 49.81 | 55.60+4.6% | 53.15-33.2% | 79.61+94.5% | 40.94-36.5% | 64.44+32.8% | 48.52-43.3% | 85.58+3790.0% | 2.20 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -26.12 | -43.94 | -79.03 | -3.13 | -36.21 | -3.50 | -17.16-261.6% | 10.62 | -67.03 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.90 | 13.93-43.2% | 24.52+308.7% | 6.00+64.4% | 3.65-67.4% | 11.18+68.6% | 6.63+25.3% | 5.29-93.1% | 77.11 |
| Repurchase of Common Pref Stock | -8.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 7.64 | 13.93-43.2% | 24.52+308.7% | 6.00+64.4% | 3.65-67.4% | 11.18+68.6% | 6.63+25.3% | 5.29-93.1% | 77.11 |
| Proceedsfrom Stock Options | 13.93 | 13.93-43.2% | 24.52+308.7% | 6.00+64.4% | 3.65-67.4% | 11.18 | 0.00 | 0.00-100.0% | 74.39 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.24 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.24 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -18.24 |
| Net Financing Active Other Cash Flow | -5.20 | -6.86 | -5.46 | -2.38 | -1.53 | -2.01 | -0.19 | -0.03 | 0.00 |
| Other Financing Activities Uses | -5.20 | -6.86 | -5.46 | -2.38 | -1.53 | -2.01 | -0.19 | -0.03 | 0.00 |
| Cash from Financing Activities | -6.10 | 7.07-62.9% | 19.05+426.2% | 3.62+70.8% | 2.12-76.9% | 9.17+42.4% | 6.44+22.4% | 5.26-91.1% | 58.86 |
| Net Change in Cash | 33.09 | 15.04 | -1.82-105.1% | 35.80 | -17.47-150.3% | 34.71+406.7% | 6.85-21.2% | 8.69 | -8.58 |
| Free Cash Flow | 57.89 | 24.75 | -5.81-138.0% | 15.30+69.6% | 9.02-57.3% | 21.12+41.3% | 14.95 | -9.80 | -3.09 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow ratio | 36.72 | 75.88 | - | 110.78 | 137.70 | 86.45 | 97.69 | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 170.27+25.8% | 162.46+39.0% | 145.34+22.0% | 137.50+8.5% | 135.38+14.3% | 116.88-8.7% | 119.12+0.6% | 126.74-0.5% |
| Short Term Receivables | 81.80+35.4% | 75.71+17.8% | 72.38+36.8% | 84.63+37.9% | 60.43+24.6% | 64.29+33.9% | 52.90+5.9% | 61.38+5.2% |
| Inventories | 17.06-6.1% | 18.38+9.2% | 18.35+7.2% | 17.56+1.1% | 18.16+15.2% | 16.83+13.0% | 17.11+26.2% | 17.37+32.7% |
| Other Current Assets | 11.65+45.4% | 8.18+24.3% | 7.99-6.2% | 7.74+6.2% | 8.01+1.6% | 6.58+2.3% | 8.52+9.5% | 7.29+6.4% |
| Total Current Assets | 280.77+26.5% | 264.73+29.4% | 244.06+23.5% | 247.44+16.3% | 221.97+16.5% | 204.58+3.6% | 197.64+4.2% | 212.78+3.5% |
| Net Property, Plant & Equipment | 165.67-5.6% | 167.62-5.4% | 170.52-3.7% | 173.17-0.1% | 175.47+9.7% | 177.25+21.3% | 177.01+36.1% | 173.26+50.5% |
| Total Investments and Advances | 65.34+31.6% | 64.97+37.1% | 65.28+50.6% | 61.40+54.0% | 49.66+50.9% | 47.40+81.5% | 43.34+47.3% | 39.88+57.8% |
| Intangible Assets | 5.16-10.7% | 5.31-10.6% | 5.47-10.2% | 5.62-10.1% | 5.78-9.8% | 5.94-9.5% | 6.09-9.4% | 6.25-9.2% |
| Other Assets | 0.18-55.0% | 0.23-48.9% | 0.29-42.0% | 0.34-39.3% | 0.40-34.4% | 0.45-31.8% | 0.50-30.6% | 0.56-27.3% |
| Total Assets | 517.11+14.1% | 502.87+15.4% | 485.63+14.4% | 487.97+12.8% | 453.27+16.1% | 435.61+15.6% | 424.59+19.0% | 432.72+22.4% |
| Short Term Debt Incl. Current Port. of LT Debt | 14.37+2.9% | 14.27+2.9% | 14.18+25.7% | 14.09+50.4% | 13.96+128.1% | 13.87+139.6% | 11.28+87.7% | 9.37+51.4% |
| Accounts Payable | 19.96+30.1% | 20.61+60.3% | 19.01+13.5% | 15.83-33.6% | 15.34-26.5% | 12.86-49.0% | 16.75-13.8% | 23.85+6.7% |
| Other Current Liabilities | 20.39+25.2% | 17.64+22.5% | 13.97+22.3% | 19.24+12.7% | 16.29+13.6% | 14.40+12.0% | 11.42+3.5% | 17.07-0.8% |
| Total Current Liabilities | 54.72+20.1% | 52.53+27.7% | 47.16+19.5% | 49.15-2.3% | 45.58+10.2% | 41.13-6.2% | 39.45+8.2% | 50.29+9.9% |
| Long Term Debt | 78.22-8.9% | 80.29-8.4% | 82.24-8.3% | 84.18-7.0% | 85.83-6.3% | 87.67-2.6% | 89.65+3.9% | 90.47+10.4% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 132.94+1.2% | 132.82+3.1% | 129.40+0.2% | 133.33-5.3% | 131.42-1.1% | 128.80-3.8% | 129.10+5.2% | 140.75+10.2% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 384.17+19.4% | 370.04+20.6% | 356.23+20.6% | 354.64+21.5% | 321.86+25.0% | 306.81+26.3% | 295.49+26.3% | 291.97+29.2% |
| Total Shareholders Equity | 384.17+19.4% | 370.04+20.6% | 356.23+20.6% | 354.64+21.5% | 321.86+25.0% | 306.81+26.3% | 295.49+26.3% | 291.97+29.2% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 384.17+19.4% | 370.04+20.6% | 356.23+20.6% | 354.64+21.5% | 321.86+25.0% | 306.81+26.3% | 295.49+26.3% | 291.97+29.2% |
| Total Liabilities & Stockholders Equity | 517.11+14.1% | 502.87+15.4% | 485.63+14.4% | 487.97+12.8% | 453.27+16.1% | 435.61+15.6% | 424.59+19.0% | 432.72+22.4% |
| Book Value Per Share per share | 7.53+18.2% | 7.23+18.9% | 6.98+18.7% | 7.01+19.2% | 6.37+21.8% | 6.08+22.3% | 5.88+22.0% | 5.88+24.6% |
| Tangible Book Value Per Share per share | 7.43+18.9% | 7.13+19.6% | 6.88+19.4% | 6.89+19.6% | 6.25+22.5% | 5.96+23.1% | 5.76+22.8% | 5.76+25.8% |
| Full-Time Employees people | - | - | - | 398+11.5% | - | - | - | 357+13.7% |
| Price to Book Ratio ratio | 7.63 | 6.37 | 4.59 | 5.66 | 5.17 | 7.24 | 7.58 | 10.51 |
| Return on Assets % | 6.86 | 5.16 | 4.72 | 3.59 | 3.10 | 1.75 | 0.76 | 2.64 |
| Return on Equity % | 9.44 | 7.16 | 6.59 | 5.11 | 4.52 | 2.59 | 1.13 | 4.00 |
| Return on Invested Capital % | 3.06 | 0.49 | -1.44 | 5.30 | 1.24 | -0.14 | -2.92 | 5.18 |
| Quick Ratio ratio | 4.82 | 4.69 | 4.79 | 4.68 | 4.47 | 4.56 | 4.58 | 3.89 |
| Current Ratio ratio | 5.13 | 5.04 | 5.18 | 5.03 | 4.87 | 4.97 | 5.01 | 4.23 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 14.16+179.3% | 2.21 | -6.30 | 23.24+17.3% | 5.07 | -0.55 | -11.25 | 19.81+52.5% |
| Depreciation | 3.63+23.5% | 3.62+27.9% | 3.27+21.6% | 3.09+108.8% | 2.94+121.1% | 2.83+114.4% | 2.69+94.9% | 1.48+28.7% |
| Other Funds (Non Cash) | 9.25-7.3% | 10.64-7.2% | 12.88+0.4% | 10.94+16.5% | 9.98-7.3% | 11.47+4.0% | 12.83+11.0% | 9.39+7.6% |
| Funds from Operations | 27.04+50.2% | 16.47+19.9% | 9.85+130.7% | 37.27+21.5% | 18.00+60.9% | 13.74+79.1% | 4.27-53.0% | 30.67+34.1% |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -9.31-327.6% | -0.28 | 6.54+180.7% | -22.25 | 4.09 | -5.53-150.9% | 2.33 | -8.43 |
| Cash from Operating Activities | 17.72-19.7% | 16.19+97.2% | 16.38+148.2% | 15.01-32.5% | 22.08+116.9% | 8.21-55.7% | 6.60-8.3% | 22.24+120.4% |
| Capital Expenditures | -2.04 | -1.93 | -1.26 | -2.19 | -2.63 | -8.13 | -14.21 | -13.79 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -0.67 | -0.89 | -2.94 | -14.20 | -0.75 | -0.90 | -0.93 | -0.86 |
| Purchase of Investments | -10.62 | -11.85 | -17.19 | -28.85 | -14.54 | -15.54 | -13.43 | -15.60 |
| Sale Or Maturity of Investments | 9.95-27.9% | 10.96-25.2% | 14.25+14.0% | 14.65-0.5% | 13.80-8.7% | 14.65+20.2% | 12.50+12.4% | 14.73-21.3% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -2.71 | -2.82 | -4.20 | -16.39 | -3.38 | -9.03 | -15.14 | -14.65 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -6.58-544.6% | 2.86+59.8% | 1.56-83.4% | 1.25-82.8% | 1.48-74.4% | 1.79-59.6% | 9.41+33.9% | 7.26+422.3% |
| Repurchase of Common Pref Stock | -8.55 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 1.97+33.1% | 2.86+59.8% | 1.56-83.4% | 1.25-82.8% | 1.48-74.4% | 1.79-59.6% | 9.41+33.9% | 7.26+422.3% |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 13.93-43.2% | 0.00 | 0.00 | 0.00 | 24.52+308.7% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.30 | -0.17 | -4.54 | -0.19 | -0.32 | -0.15 | -6.21 | -0.15 |
| Other Financing Activities Uses | -0.30 | -0.17 | -4.54 | -0.19 | -0.32 | -0.15 | -6.21 | -0.15 |
| Cash from Financing Activities | -6.88-688.0% | 2.69+64.0% | -2.98-193.1% | 1.06-85.1% | 1.17-78.8% | 1.64-61.9% | 3.20+50.2% | 7.11+442.7% |
| Net Change in Cash | 8.13-59.1% | 16.06+1834.9% | 9.20 | -0.31-102.1% | 19.87 | 0.83-83.8% | -5.34 | 14.70+344.1% |
| Free Cash Flow | 15.68-19.4% | 14.26+17725.0% | 15.13 | 12.83+51.7% | 19.45 | 0.08-95.5% | -7.61 | 8.46+276.0% |
| Price to Free Cash Flow ratio | 36.72 | 37.74 | 34.40 | 75.77 | 80.17 | - | - | - |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Biopsy Kits | 2.10 | 2.61 | +24.4% | 0.9% |
| Consolidation, Policy | 1.20 | 2.08 | +73.9% | 0.8% |
| Epicel | 36.62 | 32.07 | -12.4% | 11.6% |
| MACI Implants And Kits | 197.31 | 239.51 | +21.4% | 86.7% |
| Total | 237.22 | 276.26 | +16.5% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 237.22 | 276.26 | +16.5% | 100.0% |
| Total | 237.22 | 276.26 | +16.5% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 10.64% | 5.4M | 50.4M | 513.33K |
| 2026-10-15 | 10.35% | 5.2M | 50.6M | 508.81K |
| 2026-09-30 | 10.28% | 5.2M | 50.6M | 501.53K |
| 2026-09-15 | 10.84% | 5.5M | 50.6M | 562.09K |
| 2026-08-31 | 9.41% | 4.8M | 50.6M | 580.36K |
| 2026-08-14 | 9.34% | 4.7M | 50.6M | 581.62K |
| 2026-07-31 | 8.76% | 4.4M | 50.6M | 633.70K |
| 2026-07-15 | 9.12% | 4.6M | 50.5M | 644.87K |
| 2026-06-30 | 9.74% | 4.9M | 50.5M | 662.07K |
| 2026-06-15 | 10.49% | 5.3M | 50.4M | 659.65K |
| 2026-05-29 | 10.06% | 5.1M | 50.5M | 655.27K |
| 2026-05-15 | 10.58% | 5.3M | 50.5M | 648.72K |
| 2026-04-30 | 9.87% | 5.0M | 50.4M | 598.58K |
| 2026-04-15 | 10.09% | 5.1M | 50.3M | 577.23K |
| 2026-03-31 | 10.70% | 5.4M | 50.3M | 584.30K |
| 2026-03-13 | 10.04% | 5.0M | 50.2M | 519.43K |
| 2026-02-27 | 9.56% | 4.8M | 50.2M | 527.03K |
| 2026-02-13 | 9.59% | 4.8M | 50.0M | 543.78K |
| 2026-01-30 | 9.20% | 4.6M | 50.0M | 608.58K |
| 2026-01-15 | 8.68% | 4.3M | 50.0M | 619.69K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 20.00 | 35.00 | 39.90 | 0.00 | 654.2% | 0.00 | 0.00 | 0.940 | -0.445 | 0.010 |
| call | 22.50 | 32.50 | 37.40 | 0.00 | 589.4% | 0.00 | 0.00 | 0.931 | -0.442 | 0.011 |
| call | 25.00 | 30.00 | 34.90 | 0.00 | 532.3% | 0.00 | 0.00 | 0.923 | -0.438 | 0.012 |
| call | 30.00 | 25.00 | 29.90 | 0.00 | 435.0% | 0.00 | 0.00 | 0.904 | -0.424 | 0.014 |
| call | 35.00 | 20.00 | 24.90 | 0.00 | 377.7% | 0.00 | 0.00 | 0.881 | -0.404 | 0.017 |
| call | 40.00 | 15.00 | 19.90 | 0.00 | 302.9% | 0.00 | 0.00 | 0.852 | -0.377 | 0.019 |
| call | 45.00 | 10.00 | 14.90 | 12.44 | 235.3% | 27.00 | 0.00 | 0.812 | -0.341 | 0.023 |
| call | 50.00 | 5.00 | 9.90 | 3.50 | 171.6% | 22.00 | 0.00 | 0.753 | -0.293 | 0.027 |
| call | 55.00 | 2.10 | 5.50 | 4.90 | 126.6% | 24.00 | 0.00 | 0.637 | -0.230 | 0.032 |
| call | 60.00 | 0.15 | 3.50 | 1.75 | 102.8% | 6.00 | 0.00 | 0.423 | -0.229 | 0.033 |
| call | 65.00 | 0.00 | 3.20 | 0.00 | 145.8% | 0.00 | 0.00 | 0.328 | -0.283 | 0.031 |
| call | 70.00 | 0.00 | 5.00 | 0.00 | 187.5% | 0.00 | 0.00 | 0.281 | -0.341 | 0.028 |
| call | 75.00 | 0.00 | 5.00 | 0.00 | 219.7% | 0.00 | 0.00 | 0.253 | -0.378 | 0.027 |
| call | 80.00 | 0.00 | 5.00 | 0.00 | 247.9% | 0.00 | 0.00 | 0.233 | -0.408 | 0.026 |
| call | 85.00 | 0.00 | 5.00 | 0.00 | 273.3% | 0.00 | 0.00 | 0.218 | -0.434 | 0.025 |
| put | 20.00 | 0.00 | 5.00 | 0.00 | 688.5% | 0.00 | 0.00 | -0.060 | -0.442 | 0.010 |
| put | 22.50 | 0.00 | 5.00 | 0.00 | 620.5% | 0.00 | 0.00 | -0.069 | -0.440 | 0.011 |
| put | 25.00 | 0.00 | 5.00 | 0.00 | 560.9% | 0.00 | 0.00 | -0.077 | -0.435 | 0.012 |
| put | 30.00 | 0.00 | 5.00 | 0.00 | 459.6% | 0.00 | 0.00 | -0.096 | -0.421 | 0.014 |
| put | 35.00 | 0.00 | 5.00 | 0.65 | 374.7% | 1.00 | 0.00 | -0.119 | -0.400 | 0.017 |
| put | 40.00 | 0.00 | 5.00 | 0.00 | 300.5% | 0.00 | 0.00 | -0.148 | -0.372 | 0.019 |
| put | 45.00 | 0.00 | 5.00 | 6.00 | 233.5% | 1.00 | 0.00 | -0.188 | -0.336 | 0.023 |
| put | 50.00 | 0.00 | 5.00 | 10.20 | 170.2% | 2.00 | 0.00 | -0.247 | -0.287 | 0.027 |
| put | 55.00 | 0.10 | 5.00 | 0.65 | 106.6% | 1.00 | 0.00 | -0.363 | -0.224 | 0.032 |
| put | 60.00 | 0.70 | 5.50 | 0.00 | 129.1% | 0.00 | 0.00 | -0.574 | -0.228 | 0.033 |
| put | 65.00 | 5.10 | 10.00 | 0.00 | 165.3% | 0.00 | 0.00 | -0.674 | -0.284 | 0.030 |
| put | 70.00 | 10.00 | 15.00 | 0.00 | 190.4% | 0.00 | 0.00 | -0.719 | -0.333 | 0.028 |
| put | 75.00 | 15.00 | 20.00 | 0.00 | 222.9% | 0.00 | 0.00 | -0.747 | -0.370 | 0.027 |
| put | 80.00 | 20.00 | 25.00 | 0.00 | 266.4% | 0.00 | 0.00 | -0.767 | -0.399 | 0.026 |
| put | 85.00 | 25.00 | 30.00 | 0.00 | 277.1% | 0.00 | 0.00 | -0.782 | -0.424 | 0.025 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-09 | SEC |
| 2026-11-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-10 | SEC |
| 2026-11-12 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-09 | SEC |
| 2026-11-10 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-09 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-09 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-11-06 | 144/A | SEC | ||
| 2026-11-06 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-11-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-05 | SEC |
| 2026-11-06 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-04 | SEC |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-11-05 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-05 | 8-K | Current report | 2026-11-05 | SEC |
| 2026-11-04 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-14 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-12 | SEC |
| 2026-08-13 | SCHEDULE 13G/A | SEC | ||
| 2026-08-12 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-08-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-03 | SEC |
| 2026-08-03 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-31 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-30 | SEC |
| 2026-07-30 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-30 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-07-30 | 8-K | Current report | 2026-07-30 | SEC |
| 2026-06-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-26 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 5.79M | 10 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 780.11K | 2 |
| 2026-07 | 0 | 0 | 220.05K | 1 |
| 2026-06 | 0 | 0 | 2.64M | 7 |
| 2026-05 | 0 | 0 | 947.75K | 5 |
| 2026-04 | 0 | 0 | 121.52K | 1 |
| 2026-03 | 0 | 0 | 1.60M | 3 |
| 2026-02 | 0 | 0 | 242.62K | 1 |
| 2026-01 | 0 | 0 | 404.80K | 1 |
| 2025-12 | 0 | 0 | 254.16K | 3 |
| 2025-11 | 0 | 0 | 674.67K | 3 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 15.85% |
| STATE STREET CORP | 6.26% |
| CONGRESS ASSET MANAGEMENT CO | 4.98% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.42% |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 3.83% |
| BNP Paribas Asset Management Holding S.A. | 3.21% |
| Conestoga Capital Advisors, LLC | 3.07% |
| GW&K Investment Management, LLC | 3.00% |
| Soleus Capital Management, L.P. | 2.86% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.74% |
Funds
| Fund | % owned |
|---|---|
| iShares Core S&P Small-Cap ETF | 6.03% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 3.17% |
| iShares Russell 2000 ETF | 2.62% |
| CONESTOGA SMALL CAP FUND | 2.56% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.34% |
| Congress Small Cap Growth Fund | 2.13% |
| Loomis Sayles Small Cap Growth Fund | 1.27% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.14% |
| Fidelity Small Cap Index Fund | 1.10% |
| iShares Russell 2000 Growth ETF | 0.93% |
OakChart. VCEL. Cached 15 minutes. Terms